

Valby, 25 January 2017

Lundbeck and IBM Watson Health form collaboration on technology for developing innovative medicine

The collaboration will ensure Lundbeck's access to the Watson computer technology and large sets of data, which will provide new opportunities in the development of medicine to treat psychiatric and neurological disorders.

H. Lundbeck A/S (Lundbeck) is collaborating with IBM's Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck's expertise in the treatment of psychiatric and neurological disorders with IBM's cognitive and knowledge-based analytics to foster the discovery and development of new innovative treatments of disorders such as schizophrenia and Parkinson's disease.

"We strive to develop treatments that affect the underlying biological mechanisms of psychiatric and neurological disorders rather than treating only symptoms. By combining our expertise in brain research with IBM's cognitive computer technology, we expect to improve our foundation for this work, so we can develop new and improved treatments for the 425 million people who suffer from the psychiatric and neurological disorders which Lundbeck focuses on," says Anders Gersel Pedersen, Executive Vice President, Research & Development at Lundbeck.

Better understanding of diseases

This collaboration will help Lundbeck establish an innovative approach and new platform for real world evidence and advanced analytics where Lundbeck can take advantage of Watson technology across clinical data from millions of anonymized patient lives made available through the Watson Health Cloud.

In addition, this platform will allow Lundbeck to use the Watson technologies across additional Lundbeck data (clinical or other) as well as claims data that will be provided through this collaboration and made available in the Watson Health Cloud. Finally, Lundbeck will leverage IBM Watson for drug discovery to take advantage of a knowledge-driven approach and in support of the identification of potential new drug targets and alternative drug indications to accelerate discovery and advance the development of therapies.

"IBM can help create data-driven hypotheses based on Lundbeck's questions, which can then be used in further research on fighting psychiatric and neurological disorders. Firstly, we will launch projects within schizophrenia and Parkinson's disease, which we hope will help us better understand these diseases and possible treatments," says Anders Gersel Pedersen.



Contacts

Mads Kronborg
Senior Director, Corporate Communication
Mobile: +45 30 83 28 51
E-mail: mavk@lundbeck.com

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.

An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.